Accession Number : AD1052109


Title :   RUNX1T1 Amplification Induces Small Cell Cancer


Descriptive Note : Technical Report,01 Sep 2016,31 Aug 2017


Corporate Author : Case Western Reserve University Cleveland United States


Personal Author(s) : Dowlati, Afshin


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/1052109.pdf


Report Date : 01 Sep 2017


Pagination or Media Count : 14


Abstract : Small cell lung cancer (SCLC) is one of the deadliest cancers encountered by oncologists, with 5-year survival rates of less than 2% for patients with metastatic disease. Current thinking is that small cell lung cancer (SCLC) arises from a small population of specific neuroendocrine-like cells in the lung and is driven principally by concurrent mutation of two genes, TP53 and RB1. While this maybe true for the majority of every-day SCLC patients, there are two other clinically-important subgroups of cancer patients with small cell disease; so-called combined small cell lung cancer and extra-pulmonary small cell cancer. In combined SCLC the tumors consist of both a SCLC component and a second subtype of lung cancer, such as adenocarcinoma, and it is believed that the second, more differentiated component has transformed into a small cell cancer. Similarly, extra-pulmonary small cell tumors have primary tumors that arise outside the lung, such as in the prostate or GI tract, and transform into a small cell cancer. So in reality the term small cell simply describes a microscopic appearance, or phenotype. Clinically, however, this small cell phenotype is of great importance because it is treated the same, regardless of whether it is pulmonary, combined or extra-pulmonary and predicts the same aggressive disease course with high mortality.


Descriptors :   lung cancer , cells , amplification , patients , survivability , metastasis , mutations , genes , neoplasms , cell lines


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE